Most Favored Nation and What's Next

Most companies, and even policymakers, are betting big on importing international drug prices — but what does that really mean for cancer care in America? In this episode of Value-Based Voices, Jayson Slotnik, JD, MPH, Partner, Health Policy Strategies, Inc., dives into the evolving landscape of drug pricing reforms, unlocking why policies like the Most Favored Nation (MFN) and the Global Benchmark could reshape how medicines reach patients, providers, and payers. You’ll discover ...